argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
argenx (ARGX) reports the results of its Extraordinary General Meeting of Shareholders and the appointment of Thomas M. Brakel and Khurem Farooq as non-executive directors to the Board.
Rhea-AI Summary
argenx (ARGX) reports the results of its Extraordinary General Meeting of Shareholders and the appointment of Thomas M. Brakel and Khurem Farooq as non-executive directors to the Board.
Chairperson Tim Van Hauwermeiren said the new directors bring leadership and expertise that support argenx’s long-term “Vision 2030,” focused on scientific innovation, shareholder value and patient impact. Detailed voting results and related meeting documents are made available on the company’s investor website.
Positive
- None.
Negative
- None.
Key Terms
non-executive directors financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
September 17, 2026 – 22:01PM CET
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company’s Board of Directors.
“We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. Our focus at argenx today remains as ever before, on our scientific innovation mission, delivering value for shareholders, and always deepening the impact we make for patients and their communities. As we look ahead to Vision 2030 and beyond, we are building a company, and a board, with the strength and perspective to sustain and grow what argenx contributes to patients, science, and society for decades to come,” said Tim Van Hauwermeiren, Chairperson of the Board of argenx.
The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is the global immunology innovation company committed to improving the lives of people suffering from diseases with high unmet need. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Where can investors find the detailed voting results of the argenx Extraordinary General Meeting?
The voting result and all documents related to the Extraordinary General Meeting of Shareholders are available on the argenx website at www.argenx.com/investors/shareholder-meetings.
What roles will Thomas M. Brakel and Khurem Farooq have at argenx?
Thomas M. Brakel and Khurem Farooq have been appointed as non-executive directors on the argenx Board of Directors.
How does argenx describe the strategic context for these board appointments?
The company links the appointments to its long-term “Vision 2030,” stating that it is building a board with the strength and perspective to sustain and grow argenx’s contributions to patients, science and society for decades.